ResMed Inc. $RMD Shares Acquired by Deutsche Bank AG

Deutsche Bank AG grew its stake in ResMed Inc. (NYSE:RMD) by 126.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,413,477 shares of the medical equipment provider’s stock after purchasing an additional 787,949 shares during the quarter. Deutsche Bank AG’s holdings in ResMed were worth $340,464,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of RMD. Landscape Capital Management L.L.C. boosted its holdings in shares of ResMed by 123.2% during the 3rd quarter. Landscape Capital Management L.L.C. now owns 49,017 shares of the medical equipment provider’s stock worth $13,417,000 after purchasing an additional 27,060 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of ResMed by 37.2% during the 4th quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock worth $262,027,000 after purchasing an additional 294,124 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of ResMed by 20.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 112,755 shares of the medical equipment provider’s stock worth $30,847,000 after purchasing an additional 18,966 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of ResMed by 3.8% during the 3rd quarter. Rhumbline Advisers now owns 318,937 shares of the medical equipment provider’s stock worth $87,302,000 after purchasing an additional 11,696 shares during the last quarter. Finally, Intech Investment Management LLC boosted its holdings in shares of ResMed by 40.9% during the 3rd quarter. Intech Investment Management LLC now owns 31,299 shares of the medical equipment provider’s stock worth $8,567,000 after purchasing an additional 9,083 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Activity

In related news, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $193.96, for a total transaction of $968,054.36. Following the transaction, the chief executive officer owned 466,256 shares of the company’s stock, valued at approximately $90,435,013.76. This represents a 1.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 16,973 shares of company stock worth $3,580,754. 0.65% of the stock is owned by corporate insiders.

ResMed Stock Down 1.6%

ResMed stock opened at $193.78 on Thursday. ResMed Inc. has a fifty-two week low of $180.26 and a fifty-two week high of $293.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The firm has a 50 day moving average price of $211.53 and a 200 day moving average price of $236.09. The company has a market capitalization of $28.11 billion, a PE ratio of 18.69, a price-to-earnings-growth ratio of 1.25 and a beta of 0.80.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.42 billion. During the same period in the prior year, the firm earned $2.37 earnings per share. The firm’s revenue was up 10.8% compared to the same quarter last year. Research analysts expect that ResMed Inc. will post 11.13 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Thursday, May 14th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, May 14th. This represents a $2.40 annualized dividend and a yield of 1.2%. ResMed’s dividend payout ratio is presently 23.14%.

Analyst Ratings Changes

A number of brokerages have issued reports on RMD. KeyCorp cut their target price on ResMed from $302.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, April 27th. Wells Fargo & Company cut their target price on ResMed from $270.00 to $227.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. JPMorgan Chase & Co. began coverage on shares of ResMed in a research report on Wednesday, April 15th. They set an “overweight” rating for the company. Citigroup cut their price objective on shares of ResMed from $345.00 to $340.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, Royal Bank Of Canada raised their price objective on shares of ResMed from $314.00 to $321.00 and gave the stock an “outperform” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $286.18.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.